Core Viewpoint - The company, 东方生物, is experiencing a slight decline in stock price and is preparing for an upcoming shareholder meeting to elect a new independent director and discuss various corporate matters [1][4]. Company Announcements - 东方生物 will hold its second extraordinary general meeting of shareholders on November 20, 2025, to vote on the election of independent director 陈军泽 and adjustments to the specialized committees [1][4]. - The meeting will utilize a combination of on-site and online voting, with the record date set for November 13, 2025 [1]. - The company has received multiple medical device registration certificates for its subsidiary, 上海万子健, including test kits for gastrin-17 and NT-proBNP, which are used for diagnosing atrophic gastritis and heart failure [2][4]. Independent Director Nomination - 陈军泽 has been nominated as a candidate for independent director, with qualifications that meet regulatory requirements, including over five years of relevant work experience and no conflicts of interest [3][4]. - The nomination committee has reviewed and approved his qualifications, and he will also serve on several specialized committees if elected [2][3].

Core Insights - Oriental Bio (688298.SH) announced that its subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., along with American Hengjian, has recently obtained medical device product registration certificates in China, Australia, and Singapore [1] Domestic Medical Device Registration - Product Name: Gastrin 17 Test Kit (Flow Cytometry Method); Certificate Number: Hu Xie Zhu Zhun 20252400429; Intended Use: For in vitro quantitative detection of Gastrin 17 (G-17) levels in human serum, primarily for assisting in the diagnosis of atrophic gastritis [1] - Product Name: N-terminal Pro B-type Natriuretic Peptide Test Kit (Magnetic Particle Chemiluminescence Method); Certificate Number: Hu Xie Zhu Zhun 20252400426; Intended Use: For in vitro quantitative detection of N-terminal pro B-type natriuretic peptide (NT-proBNP) levels in human serum and plasma samples, primarily for assisting in the diagnosis of heart failure [1] International Medical Device Registration - Product Name: Healgen Rapid Test for COVID-19/Influenza A/B Antigen (Self-test); Certificate Number: DV-2024-MC24333-1; Intended Use: A lateral flow immunochromatographic test for qualitative detection and differentiation of Influenza A virus, Influenza B virus nucleoprotein antigens, and SARS-CoV-2 nucleocapsid antigens. This test is suitable for individuals aged 14 and above, requiring self-collected anterior nasal swab samples for testing. Specific testing conditions: SARS-CoV-2 infection must be tested within 7 days of symptom onset, while Influenza A and B infections must be tested within 4 days of symptom onset [1][2]

Core Insights - Oriental Bio (688298.SH) announced that its subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., along with American Hengjian, has recently obtained medical device product registration certificates in China, Australia, and Singapore [1] Domestic Medical Device Registration - Product Name: Gastrin 17 Test Kit (Flow Cytometry Method); Certificate Number: Hu Xie Zhu Zheng 20252400429; Intended Use: For in vitro quantitative detection of gastrin 17 (G-17) levels in human serum, primarily used for the auxiliary diagnosis of atrophic gastritis [1] - Product Name: N-terminal Pro B-type Natriuretic Peptide Test Kit (Magnetic Particle Chemiluminescence Method); Certificate Number: Hu Xie Zhu Zheng 20252400426; Intended Use: For in vitro quantitative detection of N-terminal pro B-type natriuretic peptide (NT-proBNP) levels in human serum and plasma samples, primarily used for the auxiliary diagnosis of heart failure [1] International Medical Device Registration - Product Name: Healgen Rapid Test for COVID-19/Influenza A/B Antigen (Self-test); Certificate Number: DV-2024-MC24333-1; Intended Use: A lateral flow immunochromatographic test for qualitative detection and differentiation of Influenza A virus, Influenza B virus nucleoprotein antigens, and SARS-CoV-2 nucleocapsid antigens. This test is suitable for individuals aged 14 and above and requires self-collected anterior nasal swab samples for testing. Specific testing conditions: SARS-CoV-2 infection must be tested within 7 days of symptom onset, and Influenza A and B infections must be tested within 4 days of symptom onset [1][2]